Q-omics provides the consensus-scored SAMD4A profile across patient tissues and cancer cell-line models. SAMD4A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SAMD4A is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SAMD4A RNA expression shows 21,032 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BLCA, and LSCC as cancer lineages where SAMD4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD4A survival associations across molecular data types. SAMD4A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD4A RNA expression–survival associations across cancer types. High SAMD4A expression shows unfavorable associations in UVM, MESO, UCEC, ACC and LGG, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SAMD4A RNA expression.
This table summarizes SAMD4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SAMD4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD4A shows lower tumor expression in BLCA, LUAD, LUSC, UCEC and BRCA and higher tumor expression in THCA. The BLCA box plot shows higher SAMD4A RNA expression in normal versus tumor tissue (log2 FC = −1.948, t-test p < 0.001).
This table shows molecular features associated with SAMD4A in patient tissues and cancer cell lines. In patient samples, SAMD4A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
